Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of …

PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell
lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus …

Learning Objectives After completing this course, the reader will be able to: Describe the
pathogenesis and clinical presentation of Kaposi's sarcoma, with a special emphasis on …

BACKGROUND A significant share of the cost of cancer care is concentrated in the end‐of‐life
period. Although quality measures of aggressive treatment may guide optimal care during …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Importance Patients with cancer are known to have increased risk of COVID-19 complications,
including death. Objective To determine the association of COVID-19 vaccination with …

Central nervous system ( CNS ) prophylaxis for diffuse large B ‐cell lymphoma ( DLBCL ) is
controversial with even less evidence in the era of R‐CHOP (rituximab, cyclophosphamide, …

Chimeric antigen receptor (CAR) T-cell therapy has the potential to transform the way in which
hematological cancers such as leukemia, lymphoma, and multiple myeloma are treated. It …

Purpose: The purpose of this study was to determine if clinical benefits of novel anticancer
drugs, measured by the ASCO Value Framework and European Society of Medical Oncology (…

Purpose To describe the modern incidence and predictors of ICU admission for adult patients
newly diagnosed with a hematologic malignancy. Methods We conducted a population-…